Fructose

Parenteral Nutrition (Intravenous)

The dosage of Fructose for nutritional support is highly individualized based on the patient's caloric requirements, age, and metabolic state.

• Standard Infusion Rate: Healthcare providers typically limit the infusion rate to 0.5 grams per kilogram of body weight per hour. Exceeding this rate increases the risk of metabolic complications such as lactic acidosis.
• Daily Maximum: While there is no absolute maximum, it is generally integrated into a total parenteral nutrition (TPN) regimen where carbohydrates provide 50-70% of total non-protein calories.

Diagnostic Breath Testing

• Standard Dose: For the diagnosis of fructose malabsorption, a standard dose of 25 grams dissolved in 200-250 mL of water is commonly used.
• Alternative Dose: Some protocols utilize 50 grams, though this higher dose may produce false positives by overwhelming the normal absorptive capacity of the small intestine.

Allergen Testing

• Dosage: In standardized chemical allergen testing, a minute, standardized concentration (often 1% to 5% in a petrolatum base) is applied to the skin. This is strictly performed by a specialist.

Fructose must be used with extreme caution in the pediatric population due to the risk of undiagnosed Hereditary Fructose Intolerance (HFI), a potentially fatal condition.

• Infants and Children: Dosage is strictly calculated based on body surface area or weight (e.g., 0.25-0.5 g/kg/hr for IV use).
• Contraindication: It is generally avoided in neonates until HFI has been ruled out.

Renal Impairment

Patients with impaired kidney function may require slower infusion rates. While Fructose is primarily metabolized by the liver, the associated risk of hyperuricemia (elevated uric acid) can exacerbate renal issues or trigger gout. Close monitoring of serum electrolytes and uric acid is required.

Hepatic Impairment

Since the liver is the primary organ for Fructose metabolism, patients with hepatic cirrhosis or acute liver failure are at high risk for Fructose-induced metabolic stress. Dosage should be significantly reduced, or Fructose should be avoided entirely in favor of glucose, depending on the severity of the liver dysfunction.

Elderly Patients

Older adults often have a higher prevalence of subclinical renal or hepatic insufficiency. Dosing should start at the lower end of the spectrum, with frequent monitoring of blood glucose and acid-base balance.

Intravenous Administration

• Fructose infusions must be administered by a healthcare professional.
• The solution should be inspected for particulate matter or discoloration before use.
• It is often administered through a central venous catheter if part of a concentrated TPN formula.

Oral Diagnostic Use

• Preparation: Dissolve the prescribed amount of powder in the specified volume of water.
• Fasting: Patients must typically fast for 8-12 hours before the test.
• Timing: The solution should be consumed within 5-10 minutes. Physical activity should be restricted during the test period to ensure accurate breath samples.

In a clinical setting (IV), a missed dose is managed by the nursing staff. If you are undergoing a diagnostic test and miss the scheduled time, contact the facility immediately. Do not double the dose to "catch up," as this can cause severe gastrointestinal distress or metabolic imbalances.

Signs of Fructose overdose (particularly via rapid IV infusion) include:

• Lactic Acidosis: Rapid breathing, confusion, and muscle pain.
• Hyperuricemia: Joint pain or signs of kidney stones.
• Osmotic Diuresis: Excessive urination and dehydration.

In case of suspected overdose, the infusion must be stopped immediately. Emergency measures include correcting the acid-base balance with sodium bicarbonate and providing supportive care for renal function.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or the rate of administration without medical guidance.

When administered orally for diagnostic purposes, the most common side effects are gastrointestinal in nature. These occur because unabsorbed Fructose draws water into the bowel (osmotic effect) and is fermented by gut bacteria.

• Abdominal Bloating: A feeling of fullness or pressure in the abdomen, often starting 30 to 90 minutes after ingestion.
• Flatulence: Increased gas production due to bacterial fermentation.
• Osmotic Diarrhea: Loose, watery stools that typically resolve once the Fructose has cleared the digestive tract.
• Abdominal Cramping: Mild to moderate waves of discomfort as the intestines process the sugar load.

These are more frequently associated with intravenous administration or higher oral doses:

• Nausea and Vomiting: Often related to the speed of infusion or the concentration of the oral solution.
• Hyperuricemia: A transient increase in uric acid levels. Fructose metabolism consumes ATP rapidly, leading to the production of uric acid as a byproduct. This may feel like a dull ache in the joints.
• Diuresis: Increased urination as the body attempts to clear excess sugar or metabolites.

• Lactic Acidosis: A serious metabolic condition where the blood becomes too acidic. Symptoms include extreme fatigue, rapid heart rate, and deep, labored breathing (Kussmaul breathing).
• Hypophosphatemia: Low levels of phosphorus in the blood, caused by the rapid "trapping" of phosphate in the liver during Fructose phosphorylation.
• Local Irritation: Pain or inflammation at the site of an intravenous injection.

> Warning: Stop taking Fructose (if oral) or alert your medical team immediately if you experience any of the following:

• Signs of an Allergic Reaction: Hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. While rare, anaphylaxis can occur, especially when Fructose is used as a standardized chemical allergen.
• Severe Upper Abdominal Pain: This could indicate acute liver stress or swelling.
• Jaundice: Yellowing of the eyes or skin, which may signal acute hepatic dysfunction, particularly in those with underlying metabolic disorders.
• Confusion or Altered Mental Status: May be a sign of severe metabolic acidosis or electrolyte imbalance.
• Seizures: Can occur if blood sugar levels or electrolyte balances shift too rapidly.

Prolonged or excessive exposure to Fructose, particularly in parenteral nutrition, has been linked to:

• Hepatic Steatosis (Fatty Liver): Because Fructose is primarily converted into lipids in the liver, long-term use can lead to fat accumulation in liver cells.
• Metabolic Syndrome Components: Including increased triglycerides and uric acid, which may contribute to cardiovascular risk or gout over time.
• Mineral Depletion: Chronic use may lead to persistent low levels of copper or phosphorus if not properly supplemented in the TPN formula.

There are currently no FDA black box warnings specifically for Fructose. However, it carries a de facto contraindication for patients with Hereditary Fructose Intolerance (HFI), as administration in these individuals can lead to rapid liver failure and death. This is considered a critical safety warning that overrides all other clinical considerations.

Report any unusual symptoms to your healthcare provider. Side effects are often manageable by adjusting the rate of administration or the concentration of the solution.

Fructose is generally safe when used as directed for diagnostic or nutritional purposes, but it carries specific risks that must be managed by a healthcare professional. The most critical safety concern is the absolute exclusion of Hereditary Fructose Intolerance (HFI). In patients with this rare genetic disorder, the body lacks the enzyme aldolase B, leading to a toxic buildup of fructose-1-phosphate. This can cause sudden hypoglycemia, liver failure, and kidney damage.

No FDA black box warnings for Fructose. However, clinical guidelines emphasize that it must never be administered to patients with a known or suspected history of HFI.

Allergic Reactions / Anaphylaxis Risk

When used as a Standardized Chemical Allergen, there is a controlled risk of inducing an allergic response. While the goal is a localized reaction, systemic hypersensitivity (anaphylaxis) is a rare but possible complication. Testing should only be performed in facilities equipped with emergency resuscitation equipment.

Hepatotoxicity and Metabolic Risks

Fructose can cause "substrate-induced" liver stress. Because its metabolism is not regulated by the cell's energy status (ATP levels), it can deplete intracellular phosphate and ATP. This can lead to liver cell injury, especially in patients with pre-existing liver disease. Healthcare providers will monitor liver enzymes (ALT, AST) during long-term IV therapy.

Hyperuricemia and Gout

Fructose is known to increase the production of uric acid. Patients with a history of gout or uric acid kidney stones should be monitored closely, as Fructose administration can trigger an acute gout flare or contribute to stone formation.

Lactic Acidosis

Rapid intravenous administration can lead to the overproduction of lactate. This is a medical emergency characterized by a drop in blood pH. It is more common in patients with hypoxia (low oxygen) or severe sepsis.

If you are receiving Fructose intravenously, your healthcare provider will likely monitor:

• Serum Electrolytes: Specifically phosphate, potassium, and magnesium.
• Blood Lactate Levels: To screen for early signs of acidosis.
• Uric Acid Levels: Especially in patients with renal impairment.
• Liver Function Tests: To ensure the liver is processing the carbohydrate load safely.
• Blood Glucose: Although Fructose is insulin-independent, it can eventually be converted to glucose in the liver.

Fructose itself does not typically cause sedation or cognitive impairment. However, if you are undergoing a diagnostic breath test, the associated symptoms (cramping, diarrhea) may make it uncomfortable to drive. Use caution until you know how the test affects you.

Alcohol should be avoided during Fructose therapy. Alcohol interferes with gluconeogenesis and can worsen Fructose-induced hyperuricemia and lactic acidosis. In patients with HFI, alcohol can significantly increase the toxicity of even small amounts of Fructose.

In parenteral nutrition, Fructose is typically tapered or transitioned to oral intake. There is no "withdrawal syndrome" associated with Fructose, but sudden cessation of high-calorie IV fluids can cause transient hypoglycemia as the body adjusts its metabolic rate.

> Important: Discuss all your medical conditions, especially any history of metabolic disorders or gout, with your healthcare provider before starting Fructose.

• Any Fructose-containing product + Hereditary Fructose Intolerance (HFI): This is a metabolic contraindication rather than a drug-drug interaction, but it is the most critical. Use will result in severe hepatotoxicity.
• Sorbitol: Sorbitol is metabolized into Fructose in the body. Combining high doses of Sorbitol and Fructose increases the risk of osmotic diarrhea and metabolic overload exponentially.

• Insulin: While Fructose metabolism is initially insulin-independent, the liver eventually converts Fructose into glucose. This can lead to delayed hyperglycemia, requiring adjustments in insulin dosing for diabetic patients.
• Biguanides (Metformin): Metformin can increase lactate production. Since Fructose also carries a risk of lactic acidosis, the combination requires careful monitoring of blood pH, especially in patients with renal impairment.
• Loop Diuretics (Furosemide): These drugs can increase uric acid levels. When combined with Fructose, the risk of hyperuricemia and gout flares is significantly elevated.

• Thiazide Diuretics: Similar to loop diuretics, these can interfere with uric acid excretion, compounding the effects of Fructose metabolism.
• Corticosteroids: These medications can increase blood glucose levels and alter carbohydrate metabolism, potentially complicating the nutritional use of Fructose.

• Glucose: Interestingly, glucose can enhance the absorption of Fructose in the gut. While this can be beneficial in some nutritional contexts, it may interfere with the accuracy of a Fructose Breath Test.
• High-Fiber Foods: Can delay the transit of Fructose through the digestive system, potentially skewing the results of diagnostic tests.
• Alcohol: As mentioned, alcohol increases the risk of lactic acidosis and hyperuricemia associated with Fructose.

• Vitamin B6 (Pyridoxine): Given Fructose's EPC classification as a Vitamin B6 analog in certain contexts, high doses of B6 supplements might theoretically compete for metabolic pathways, though clinical data on this interaction is limited.
• Uricosuric Herbs (e.g., Celery Seed): May affect how the body handles the uric acid produced during Fructose metabolism.

Fructose can significantly affect several laboratory parameters:

• Uric Acid: Expect a transient rise in serum and urinary uric acid.
• Bilirubin: High-dose Fructose can occasionally cause a slight, transient increase in bilirubin levels.
• Serum Phosphate: May show a decrease (hypophosphatemia) shortly after administration.
• Breath Hydrogen/Methane: Used as the primary indicator in breath tests; however, recent antibiotic use or smoking can cause false results.

Mechanism of Interactions

Most Fructose interactions are pharmacodynamic, meaning they involve additive effects on metabolic pathways (like lactate or uric acid production). Some are pharmacokinetic, particularly involving the GLUT5 transporter in the gut or renal clearance of metabolites.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as they can influence how your body processes Fructose.

Conditions where Fructose must NEVER be used:

1. 1Hereditary Fructose Intolerance (HFI): This is an autosomal recessive disorder where the enzyme aldolase B is deficient. Administration of Fructose leads to a rapid accumulation of fructose-1-phosphate, causing severe hypoglycemia, liver failure, and potentially death. The mechanism is a profound depletion of ATP and inorganic phosphate in liver cells.
2. 2Known Hypersensitivity: Any previous anaphylactic or severe systemic reaction to Fructose or Fructose-containing intravenous solutions.
3. 3Acute Uric Acid Nephropathy: Because Fructose increases uric acid production, it can worsen acute crystal-induced kidney injury.

Conditions requiring a careful risk-benefit analysis by your healthcare provider:

• Gout: Due to the risk of hyperuricemia-induced flares.
• Severe Hepatic Cirrhosis: The liver may be unable to process the Fructose load, leading to metabolic acidosis.
• Diabetes Mellitus: While initially insulin-independent, the eventual conversion to glucose can complicate glycemic control.
• Severe Dehydration: The osmotic effect of Fructose (especially if excreted in urine) can worsen fluid loss.
• Lactic Acidosis: Any pre-existing state of acidosis is a strong reason to avoid Fructose infusions.

• Sorbitol: Many patients who are sensitive to Fructose or have malabsorption issues will also react to Sorbitol, as the two are biochemically linked via the polyol pathway.
• Inulin: This carbohydrate is composed of fructose chains; patients with severe fructose malabsorption may also react to inulin-containing supplements or foods.

> Important: Your healthcare provider will evaluate your complete medical history, including any family history of metabolic disorders, before prescribing or administering Fructose.

• Pregnancy Category: Fructose is generally considered safe when used in physiological amounts. For high-dose diagnostic testing or TPN, it is often classified as Category C (or equivalent).
• Risks: There is no evidence of direct teratogenicity (birth defects). However, maternal lactic acidosis or severe hypoglycemia (in the case of undiagnosed HFI) could be devastating for the fetus.
• Clinical Use: It is rarely the first choice for IV nutrition in pregnancy unless specifically indicated. Diagnostic breath tests are usually deferred until postpartum unless the clinical need is urgent.

• Passage into Milk: Fructose is a natural component of breast milk. Supplemental Fructose administered to the mother is unlikely to significantly alter the milk's composition in a way that harms a healthy infant.
• Considerations: If the nursing infant has HFI, the mother must be extremely cautious with her own Fructose intake, although the amount transferred in milk is usually very low. Always consult a pediatrician.

• Approval: Fructose is used in pediatric parenteral nutrition, but with extreme caution.
• HFI Screening: Many clinicians recommend screening for HFI before administering Fructose-containing IV fluids to infants, especially those who have not yet been introduced to fruit or sugar in their diet.
• Growth Effects: Proper caloric intake is essential for growth; however, Fructose-heavy TPN must be balanced with other nutrients to avoid fatty liver development in children.

• Renal Clearance: Older adults have a natural decline in GFR (glomerular filtration rate). This increases the risk that Fructose-induced hyperuricemia will lead to kidney stones or gout.
• Polypharmacy: The elderly are more likely to be on diuretics or metformin, increasing the risk of drug interactions.
• Monitoring: Frequent checks of acid-base status and renal function are mandatory in this population.

• Dose Adjustment: No specific formula exists, but the rate of infusion should be reduced by 25-50% in patients with a GFR < 30 mL/min.
• Dialysis: Fructose and its metabolites are small molecules and are generally cleared by hemodialysis.

• Child-Pugh Class C: Fructose is generally contraindicated or used only with extreme caution, as the liver's ability to phosphorylate and process the sugar is severely compromised.

> Important: Special populations require individualized medical assessment to ensure that the metabolic benefits of Fructose outweigh the risks.

Fructose functions as a rapidly metabolizable source of energy. Its primary molecular mechanism involves the fructokinase (ketohexokinase) enzyme. Unlike glucose, which is regulated by hexokinase and the insulin-sensitive GLUT4 transporter, Fructose enters the cell via GLUT5 and is immediately phosphorylated into fructose-1-phosphate. This bypasses the major regulatory step of glycolysis (phosphofructokinase). This "open-valve" metabolism allows for rapid energy production but can also lead to the depletion of intracellular ATP and inorganic phosphate, as the phosphorylation happens faster than the cell can regenerate these molecules.

• Onset of Effect: Intravenous Fructose begins to be metabolized almost immediately upon infusion. Oral Fructose for breath testing typically reaches the colon (if malabsorbed) within 60 to 120 minutes.
• Duration: The metabolic effects of a single bolus or short infusion typically last 2 to 4 hours.
• Tolerance: There is no known pharmacological tolerance to Fructose, though the body's ability to absorb it (via GLUT5) can be upregulated slightly with chronic exposure.

| Parameter | Value |

|---|---|

| Bioavailability | ~100% (IV); Variable (Oral) |

| Protein Binding | < 5% |

| Half-life | 15 - 30 minutes |

| Tmax | 0.5 - 1 hour (Oral) |

| Metabolism | Hepatic (Fructokinase pathway) |

| Excretion | Renal < 5%; Primarily Metabolic |

• Molecular Formula: C6H12O6
• Molecular Weight: 180.16 g/mol
• Solubility: Highly soluble in water (~4000 g/L at 25°C).
• Structure: A 6-carbon polyhydroxyketone. In solution, it primarily exists as a cyclic pyranose or furanose.

Fructose is classified as a monosaccharide caloric agent. Within the EPC system, it is recognized as a Standardized Chemical Allergen, reflecting its use in immunological diagnostics. It is related to other caloric agents like Dextrose (Glucose) and Galactose.